United States Patent 8,318,788: What Is Claimed, What It Covers, and Where It Sits in the US Weight-Loss/Layered-Bioerodible Formulation Landscape
US Patent 8,318,788 claims a layered, physically separated oral formulation and a method for affecting weight loss in which a rapidly dissolving intermediate layer releases two substantially intact sustained-release layers (drug payload layers) while preserving each payload layer’s in vivo dissolution profile relative to a single compressed tablet of the same composition, size, and shape as each payload layer.
1) What does the patent claim, in practical scope terms?
Core claim concept (independent claims 1 and 12)
Both independent claims follow the same architecture:
- Use/indication: “affecting weight loss in a patient”
- Patient step: “identifying a patient in need of weight loss”
- Formulation step: administering a layered pharmaceutical formulation with:
- First pharmaceutical layer containing a first active in a sustained-release format
- Second pharmaceutical layer containing a second active in a sustained-release format
- Intermediate layer between them that rapidly dissolves in vivo
- Separation mechanism: intermediate layer dissolution leaves first and second layers:
- “substantially intact”
- “physically separated”
- Dissolution-profile constraint (key narrowing limitation):
- dissolution profile of first active in the formulation is “substantially the same as” a single compressed tablet of the same size and shape as the first layer
- dissolution profile of second active in the formulation is “substantially the same as” a single compressed tablet matching the second layer’s composition, size and shape
- Separation timing (also narrowing): “first and second layers separate in vivo in less than 1 minute” (dependent claims)
Payload actives by claim set
- Claim set 1 (claim 1): naltrexone + bupropion
- Claim set 2 (claim 12): zonisamide + bupropion
In both sets, bupropion is the second-layer payload, and the first-layer payload varies (naltrexone vs zonisamide).
2) How broad is the claim scope? What is mandatory vs optional?
Mandatory limitations (must be met)
Independent claims require all of the following structural-and-functional elements:
- Layered formulation with three layers (first payload, intermediate, second payload)
- Intermediate layer rapidly dissolves in vivo
- Payload layers remain substantially intact and physically separated
- Each payload layer’s in vivo dissolution profile must be substantially the same as that of:
- a single compressed tablet having the same size and shape as the first layer (for naltrexone or zonisamide), and
- a single compressed tablet having the same composition, size and shape as the second layer (for bupropion)
- The method is for affecting weight loss.
Optional/narrowing limitations (added by dependent claims)
Dependent claims add further constraints on intermediate composition, sustained-release selection, dose ranges, and in vivo separation time:
- Intermediate layer composition:
- monosaccharide, disaccharide, or starch (claim 2)
- lactose (claim 3; mirrors claim 14 for the zonisamide set)
- Sustained-release carrier forms:
- naltrexone sustained-release (claim 4)
- bupropion sustained-release (claim 5)
- zonisamide sustained-release (claim 15)
- bupropion sustained release (claim 16)
- Dose ranges:
- naltrexone first layer:
- 2 mg to 35 mg (claim 6)
- 4 mg to 10 mg (claim 7)
- bupropion second layer:
- 50 mg to 200 mg (claim 8)
- 75 mg to 150 mg (claim 9)
- 85 mg to 100 mg (claim 10)
- zonisamide first layer: no explicit mg ranges in the provided dependent claims list
- bupropion second layer dose ranges parallel the naltrexone set (claims 17-19)
- Separation timing:
- first and second layers separate in vivo in less than 1 minute (claim 11; claim 20)
Claim mapping (quick coverage matrix)
| Element |
Claim 1 (naltrexone + bupropion) |
Claim 12 (zonisamide + bupropion) |
| Weight-loss method |
Yes |
Yes |
| First payload active |
Naltrexone |
Zonisamide |
| Second payload active |
Bupropion |
Bupropion |
| Three-layer architecture |
Yes |
Yes |
| Intermediate rapidly dissolves |
Yes |
Yes |
| Payload layers remain intact and separated |
Yes |
Yes |
| Dissolution profile match vs single compressed tablet |
Yes |
Yes |
| Intermediate composition limited (optional) |
monosaccharide/disaccharide/starch; lactose |
monosaccharide/disaccharide/starch; lactose |
| Sustained-release requirement (optional/dep) |
naltrexone SR; bupropion SR |
zonisamide SR; bupropion SR |
| Dose limits (optional/dep) |
naltrexone: 2-35 mg; 4-10 mg; bupropion: 50-200, 75-150, 85-100 mg |
bupropion: 50-200, 75-150, 85-100 mg |
| Separation time (optional/dep) |
< 1 minute |
< 1 minute |
3) Where is the real legal leverage: the “dissolution profile same as a single compressed tablet” limitation
The distinctive tightening force is not simply “layered” and “rapid intermediate dissolution.” It is the repeated requirement that each payload layer’s in vivo dissolution profile is “substantially the same” as the corresponding single compressed tablet with matched composition/size/shape.
That limitation does two things for the patent owner in enforcement:
- It links the layered geometry to performance equivalence. A competitor can argue different release kinetics or different geometry affects dissolution.
- It gives a measurement anchor (a defined comparator: “single compressed tablet” with the same size/shape). That comparator supports standardization in claim construction and in infringement/noninfringement testing arguments.
In a patent landscape context, this means design-arounds often must focus on:
- changing layer size/shape in a way that prevents “substantially the same” dissolution behavior, or
- changing the sustained-release mechanism or formulation so the dissolution profile differs materially, even if intermediate dissolution still separates layers.
4) Patent landscape implications: what surrounding US competitive work likely targets
A. This is an “oral layered SR + rapid intermediate dissolution” design zone
US formulation innovation for obesity/weight loss commonly includes:
- fixed-dose combinations of known actives
- extended-release and delayed-release approaches
- controlled release beads or matrices
- multilayer tablets or multiparticulate devices
Patent 8,318,788 sits specifically in the subspace of multipart or multilayer tablets where an intermediate layer is engineered to dissolve quickly and physically separate two sustained-release layers, while maintaining release equivalence.
B. Active pair coverage vs broader platform coverage
The active pairs explicitly stated are:
- naltrexone + bupropion (claim 1 and dependents)
- zonisamide + bupropion (claim 12 and dependents)
That creates a dual landscape effect:
- Direct overlap risk is highest for combinations using bupropion as one sustained-release payload plus a second sustained-release payload among naltrexone or zonisamide, delivered in a three-layer format with a rapidly dissolving intermediate layer and matching dissolution profiles.
- Platform claims risk (broader risks to layered SR approaches) is lower because independent claims still require:
- dissolution equivalence to single compressed tablets, and
- the particular active pairing set and method for weight loss.
C. Where design-arounds likely concentrate
Given the claim language, typical design-around levers are:
-
Avoid the intermediate layer’s rapid dissolution function
If the intermediate dissolves more slowly or does not produce timely physical separation, the “rapidly dissolve in vivo” and “leave … physically separated” limitations become harder to satisfy.
-
Break the “substantially intact” requirement
If payload layers deform, erode, or disintegrate before separation, the “substantially intact” limitation is implicated.
-
Break dissolution-profile equivalence
If in vivo dissolution differs from a matching single compressed tablet comparator (matched to the layer’s composition/size/shape), the performance-based limitation may fail.
-
Break the “same size and shape” comparator alignment
Even slight changes to layer geometry and how it maps to a comparator tablet can support arguments that the dissolution profiles are not “substantially the same.”
-
Timing design-around (<1 minute dependent claims)
For enforcement, claim 11 and claim 20 add a high-specificity timing requirement. If a competitor’s separation occurs at or above 1 minute, those dependent claims are easier to avoid, though the independent claims (without a separation-time limit) still remain.
5) Claim-by-claim enforcement map (what is likely easiest to prove)
Independent claim 1 (naltrexone + bupropion)
A plaintiff generally targets:
- Existence of a layered formulation with defined intermediate dissolution and preserved payload integrity
- Evidence that naltrexone and bupropion payloads are each sustained-release layers (even if SR is not explicitly required in claim 1, dependents 4 and 5 are; claim 1 still recites the payload layer and dissolution-profile equivalence)
- In vivo dissolution testing that demonstrates equivalence to comparator single compressed tablets.
Dependent claims 2-11 (intermediate composition, SR, dose, separation timing)
- Claims 2-3 (intermediate materials): likely provable from formulation composition specs and excipient bills of materials.
- Claims 4-5 (SR nature): likely provable from dosage form description, release mechanism, and dissolution curves.
- Claims 6-10 (dose windows): provable from label and manufacturing batch records.
- Claim 11 (<1 minute separation): provable from in vivo imaging or surrogate separation studies.
Independent claim 12 (zonisamide + bupropion)
Mirrors claim 1 with zonisamide substituting naltrexone. The same dissolution-profile comparator structure applies.
Dependent claims 13-20:
- Intermediate composition limited to monosaccharides/disaccharides/starch and lactose (claims 13-14)
- SR selection (claims 15-16)
- Dose ranges for bupropion (claims 17-19)
- Separation timing (<1 minute) (claim 20)
6) Competitive landscape: where risk is concentrated
Lowest-risk design positions (relative)
Based on claim structure, the lowest overlap with this patent generally comes from products that:
- do not use an intermediate layer engineered to rapidly dissolve in vivo to physically separate two intact sustained-release layers, or
- do not maintain dissolution equivalence versus matched single compressed tablets by size/shape (and composition for bupropion), or
- do not include the specific active pairing set in the independent claims (naltrexone+bupropion; zonisamide+bupropion) in a weight-loss method context.
Highest-risk design positions (relative)
Risk concentrates on:
- obesity/weight-loss oral combination products that use:
- bupropion plus naltrexone or zonisamide
- a rapidly dissolving intermediate layer
- two sustained-release payload layers engineered to remain physically separated
- measured in vivo dissolution profiles aligned to corresponding single compressed tablets.
7) Practical due diligence: what to look for when assessing infringement or freedom-to-operate
For investors and R&D teams evaluating layered oral combo strategies in this space, claim language implies a diligence checklist tied to litigation-grade proof:
- Formulation architecture: confirm three-layer tablet structure and intermediate layer function.
- Intermediate excipient selection: does it fall within monosaccharide/disaccharide/starch, specifically lactose if pursuing dependents?
- Release mechanism and payload integrity: does each payload remain substantially intact until after intermediate dissolution?
- Comparative dissolution testing: generate in vivo (or legally accepted) dissolution evidence comparing:
- dissolution of each payload in the layered product vs
- dissolution of a single compressed tablet having the same active composition, size, and shape as each payload layer.
- Separation timing: if below-1-minute separation is necessary to meet dependents, measure it.
Key Takeaways
- US 8,318,788 claims a three-layer oral formulation for weight loss where a rapidly dissolving intermediate layer physically separates two substantially intact sustained-release payload layers.
- The most constraining limitation is in vivo dissolution-profile equivalence: each payload’s dissolution profile must be “substantially the same” as that of a single compressed tablet matched to the payload layer’s composition and geometry.
- Independent claims cover two active pairings: naltrexone + bupropion and zonisamide + bupropion, each paired with a layered architecture and dissolution equivalence requirement.
- Dependent claims tighten scope through intermediate excipient choice (lactose), dose windows, and a <1 minute separation performance parameter.
FAQs
1) Does the patent cover any layered tablet, or only a specific functional architecture?
It covers only layered formulations where an intermediate layer rapidly dissolves in vivo to leave two substantially intact and physically separated sustained-release payload layers and where each payload shows substantially the same dissolution profile as a matched single compressed tablet.
2) Are the independent claims limited to sustained-release versions?
Independent claims require the payload layers and dissolution-profile equivalence; dependent claims expressly require sustained-release versions for each payload (naltrexone/zoniamide and bupropion).
3) What exact active pairs are in the independent claims?
The independent claims are for naltrexone + bupropion (claim 1) and zonisamide + bupropion (claim 12).
4) What do the intermediate layer excipient limitations cover?
Dependent claims limit the intermediate layer to monosaccharides, disaccharides, or starch, with an additional dependent limitation to lactose.
5) How does the “<1 minute” separation language affect enforcement?
It appears only in dependents (claims 11 and 20). Products with separation at or above 1 minute may avoid those dependent claims, but independent claims without that timing limitation could still be implicated if other limitations are met.
References
[1] United States Patent 8,318,788. Claims as provided in user prompt.
